Voloridge Investment Management’s Teva Pharmaceuticals TEVA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-379,586
| Closed | -$11.4M | – | 1078 |
|
|
2026
Q1 | $11.4M | Buy |
+379,586
| New | +$12.2M | 0.05% | 472 |
|
|
2024
Q3 | – | Sell |
-847,781
| Closed | -$13.8M | – | 1356 |
|
|
2024
Q2 | $13.8M | Buy |
847,781
+426,508
| +101% | +$6.57M | 0.05% | 484 |
|
|
2024
Q1 | $5.94M | Buy |
+421,273
| New | +$5.31M | 0.02% | 616 |
|
|
2023
Q4 | – | Sell |
-60,516
| Closed | -$617K | – | 1465 |
|
|
2023
Q3 | $617K | Buy |
60,516
+33,027
| +120% | +$308K | ﹤0.01% | 1177 |
|
|
2023
Q2 | $207K | Buy |
+27,489
| New | +$223K | ﹤0.01% | 1317 |
|
|
2023
Q1 | – | Sell |
-42,564
| Closed | -$388K | – | 1617 |
|
|
2022
Q4 | $388K | Buy |
+42,564
| New | +$371K | ﹤0.01% | 1309 |
|
|
2021
Q4 | – | Sell |
-114,195
| Closed | -$1.11M | – | 1841 |
|
|
2021
Q3 | $1.11M | Buy |
+114,195
| New | +$1.07M | 0.01% | 1249 |
|
|
2020
Q3 | – | Sell |
-1,014,958
| Closed | -$12.5M | – | 1500 |
|
|
2020
Q2 | $12.5M | Buy |
1,014,958
+481,796
| +90% | +$5.45M | 0.14% | 149 |
|
|
2020
Q1 | $4.79M | Buy |
+533,162
| New | +$5.46M | 0.14% | 166 |
|
|
2019
Q4 | – | Sell |
-1,603,220
| Closed | -$11M | – | 1347 |
|
|
2019
Q3 | $11M | Buy |
1,603,220
+324,347
| +25% | +$2.49M | 0.19% | 107 |
|
|
2019
Q2 | $11.8M | Buy |
+1,278,873
| New | +$15.4M | 0.33% | 63 |
|
|
2017
Q4 | – | Sell |
-233,649
| Closed | -$4.11M | – | 605 |
|
|
2017
Q3 | $4.11M | Buy |
+233,649
| New | +$5.26M | 0.09% | 209 |
|
|
2017
Q2 | – | Sell |
-683,716
| Closed | -$21.9M | – | 569 |
|
|
2017
Q1 | $21.9M | Buy |
+683,716
| New | +$23.3M | 0.53% | 39 |
|
|
2016
Q3 | – | Sell |
-464,586
| Closed | -$23.3M | – | 333 |
|
|
2016
Q2 | $23.3M | Sell |
464,586
-194,081
| -29% | -$10.3M | 0.67% | 50 |
|
|
2016
Q1 | $35.2M | Buy |
+658,667
| New | +$38.6M | 0.83% | 19 |
|
|
2015
Q4 | – | Sell |
-482,375
| Closed | -$27.2M | – | 301 |
|
|
2015
Q3 | $27.2M | Buy |
482,375
+451,575
| +1,466% | +$29.3M | 1.28% | 17 |
|
|
2015
Q2 | $1.82M | Sell |
30,800
-424,010
| -93% | -$26.2M | 0.09% | 182 |
|
|
2015
Q1 | $28.3M | Buy |
454,810
+444,512
| +4,316% | +$25.8M | 1.37% | 14 |
|
|
2014
Q4 | $592K | Sell |
10,298
-35,702
| -78% | -$1.99M | 0.03% | 175 |
|
|
2014
Q3 | $2.47M | Buy |
+46,000
| New | +$2.44M | 0.12% | 64 |
|
|
2014
Q2 | – | Sell |
-100,034
| Closed | -$5.29M | – | 115 |
|
|
2014
Q1 | $5.29M | Buy |
+100,034
| New | +$4.62M | 0.75% | 30 |
|
Other funds holding TEVA
HIIFS
PF
CI
MMH
MIFH
LIM
Voloridge Investment Management's TEVA Position: Q2 2026 in Review
Voloridge Investment Management sold out of Teva Pharmaceuticals (TEVA) in Q2 2026, closing a stake of 379,586 shares — an estimated $11.4M sold.
Voloridge Investment Management first reported a position in TEVA in Q1 2014 and held it in 21 quarters. The position peaked at $35.2M in Q1 2016. 673 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.
- Voloridge Investment Management reported no remaining Teva Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Voloridge Investment Management sold 379,586 Teva Pharmaceuticals shares in Q2 2026, an estimated $11.4M.
- Voloridge Investment Management first reported a position in Teva Pharmaceuticals in Q1 2014 and held it in 21 quarters.
- Voloridge Investment Management's Teva Pharmaceuticals position peaked at $35.2M in Q1 2016.
- 673 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.
Based on Voloridge Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.